Related Experiment Video
Updated: Mar 13, 2026
Preparation of Mitochondrial Enriched Fractions for Metabolic Analysis in Drosophila
Published on: September 30, 2015
Rapamycin enhances survival in a Drosophila model of mitochondrial disease
Adrienne Wang1, Jacob Mouser1, Jason Pitt1
1University of Washington, Department of Pathology, Seattle, WA, USA.
Insights
Rapamycin treatment extends lifespan in a Drosophila model of Leigh Syndrome, a pediatric mitochondrial disorder. This effect is independent of autophagy and linked to metabolic alterations, offering new therapeutic insights.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Pediatric mitochondrial disorders, including Leigh Syndrome (LS), are severe genetic diseases impairing mitochondrial function.
- Current treatments for LS are limited, highlighting the need for novel therapeutic strategies.
- Previous research demonstrated rapamycin's efficacy in yeast and mouse models of mitochondrial dysfunction.
Purpose of the Study:
- To investigate the effects of mechanistic target of rapamycin (TOR) inhibition in a Drosophila model of complex I deficiency, a model for LS.
- To elucidate the mechanism underlying TOR inhibition's therapeutic effects in mitochondrial disorders.
- To determine if rapamycin's benefits extend to other models of mitochondrial deficiency.
Main Methods:
- Utilized a Drosophila melanogaster model with complex I deficiency (ND2 mutant) to mimic LS.
- Administered rapamycin to assess its impact on lifespan and behavioral phenotypes.
- Investigated the role of autophagy in rapamycin's observed effects.
- Analyzed metabolic changes, specifically fat storage, in response to rapamycin treatment.
Main Results:
- Rapamycin treatment significantly extended the lifespan of flies with complex I deficiency.
- Lifespan extension occurred independently of autophagy.
- Rapamycin administration rescued a fat storage defect in the mutant flies.
- Behavioral phenotypes were not significantly affected by rapamycin treatment.
Conclusions:
- TOR inhibition by rapamycin shows therapeutic potential for complex I deficiency, a model for LS.
- The mechanism of action involves metabolic regulation, particularly fat storage, rather than autophagy.
- These findings support rapamycin as a potential therapeutic agent for certain mitochondrial disorders by targeting metabolic pathways.
Abstract:
Pediatric mitochondrial disorders are a devastating category of diseases caused by deficiencies in mitochondrial function. Leigh Syndrome (LS) is the most common of these diseases with symptoms typically appearing within the first year of birth and progressing rapidly until death, usually by 6-7 years of age. Our lab has recently shown that genetic inhibition of the mechanistic target of rapamycin (TOR) rescues the short lifespan of yeast mutants with defective mitochondrial function, and that pharmacological inhibition of TOR by administration of rapamycin significantly rescues the shortened lifespan, neurological symptoms, and neurodegeneration in a mouse model of LS. However, the mechanism by which TOR inhibition exerts these effects, and the extent to which these effects can extend to other models of mitochondrial deficiency, are unknown. Here, we probe the effects of TOR inhibition in a Drosophila model of complex I deficiency. Treatment with rapamycin robustly suppresses the lifespan defect in this model of LS, without affecting behavioral phenotypes. Interestingly, this increased lifespan in response to TOR inhibition occurs in an autophagy-independent manner. Further, we identify a fat storage defect in the ND2 mutant flies that is rescued by rapamycin, supporting a model that rapamycin exerts its effects on mitochondrial disease in these animals by altering metabolism.
